(ABT) Community Analysis from
Bulls REASONS TO BUY
|
100%
agree
35 votes
|
New Medicare reform has led to the coverage Humira |
|
100%
agree
5 votes
|
Abbott is awaiting FDA approval for additional indications of Humira |
|
100%
agree
5 votes
|
Xience V drug-eluting stent has had successful late-stage clinical trials |
Bears REASONS TO SELL
|
10%
agree
10 votes
|
Medicare could negatively affect Abbott's pricing in the long run |
|
16%
agree
12 votes
|
Abbott's R&D expenditures are much less than their competition |
|
18%
agree
16 votes
|
Pipeline questions |
May 25, 2013
(Stock Blog Hub,
5/2/13)
Abbott Laboratories (ABT) recently announced that the company has launched ACCELERATOR a3600 – its next-generation track system to increase efficiency in laboratories.
A...(read more)
(Stock Blog Hub,
2/18/13)
AbbVie (ABBV) recently confirmed its sales figures for 2012 and provided guidance for 2013 as an independent company. AbbVie came into existence earlier this year following its separation from...(read more)
(The DIV-Net,
1/25/13)
Abbott Laboratories: A company I loved
At the beginning of this year, Abbott Laboratories (ABT) completed the spin-off of its branded pharmaceutical business. This business is now a separate...(read more)
Abbott Laboratories (ABT) Company Overview
Abbott Laboratories (NYSE: ABT) is the largest company in the nutritional products market and the second largest company in the worldwide market for diagnostic products. The company manufactures a number of nutritional and pharmaceutical products, laboratory diagnostics, pharmaceutical therapies and medical devices, including the arthritis medication Humira and the coronary stent Xience. In FY 2010, Abbott generated revenues of $35.17B and net earnings of $4.6B.[1]
Abbott and the rest of the pharmaceutical industry are continually under pressure from expiring patents. Patent expiration allows generic drug companies to lower prices for a certain medication by producing their own versions, increasing competition for that product's market.
(Read more at Wikinvest
) What's in this ABT analysis on Wikinvest...
- Corporate Overview
- Recent Acquisitions
- Business Segments
- Pharmaceutical Products ($19.9 billion, 56.6% of 2010 revenues)[6]
- Nutritional Products ($5.5 billion, 15.7% of 2010 revenues)[8]
- Diagnostics ($3.8 billion, 10.8% of 2010 revenues)[9]
- Vascular ($3.2 billion, 9.1% of 2010 revenues)[10]
- Research and Development ($3.7B, 10.5% of 2010 revenues)[12]
- Trends and Forces
- Government regulation challenge
- Tightening FDA Regulations
- Expiring patents threat
- Strong pipeline; diverse businesses
- Generic pharmaceuticals: direct competition
- Medicare coverage patterns
- Effect of US politics
- Competition
- References
